Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Gains from Sales and Divestitures: 2024

  • Zenas BioPharma's Gains from Sales and Divestitures was N/A to $6,028 in Q4 2024 from the same period last year, while for Dec 2024 it was $6,028, marking a year-over-year change of. This contributed to the annual value of $6,028 for FY2024, which is N/A change from last year.
  • As of Q4 2024, Zenas BioPharma's Gains from Sales and Divestitures stood at $6,028, which was up 0.02% from $6,027 recorded in Q3 2024.
  • In the past 5 years, Zenas BioPharma's Gains from Sales and Divestitures registered a high of $6,028 during Q4 2024, and its lowest value of $6,027 during Q3 2024.
  • For the 1-year period, Zenas BioPharma's Gains from Sales and Divestitures averaged around $6,028, with its median value being $6,028 (2024).